Pharmaron Plans RMB 5B CDMO Expansion; Nomura Maintains Buy

Overview

Nomura Securities issued a flash note commenting on Pharmaron’s (3759.HK) latest capital expenditure plan. On May 27, 2026, the company announced a RMB 5 billion investment to construct new commercial-stage CDMO production facilities in Hangzhou and Shaoxing. While Pharmaron has excelled in early-stage drug discovery CRO services, Nomura believes this investment demonstrates its commitment to extending downstream and providing an 'end-to-end' solution to address its current bottleneck in commercial manufacturing capacity (which accounts for only 25% of total revenue). The firm maintains its 'Buy' rating and assigns a target price of HKD 27.33 based on a DCF model.

Core views

Strategic Intent and Capacity Deployment: Pharmaron’s RMB 5 billion investment will be allocated between Hangzhou (RMB 2 billion) and Shaoxing (RMB 3 billion). The Shaoxing facility is planned to have an annual capacity of 200 tons, dedicated to producing advanced intermediates and active pharmaceutical ingredients (APIs) for obesity, diabetes, and oncology therapeutics. Construction is expected to span approximately three years, with Phase I operational by 2028 and Phase II completed by 2030. As of end-2025, the company had 34 validated/commercial-stage projects, 47 Phase II projects, and 271 Phase I/II projects. To retain these pipeline assets into commercial production, the company must increase its corresponding capacity reserves. Financial Impact and Funding Support: Management expects the investment plan to have no material impact on 2026 financials. Nomura estimates that assuming annual expenditures of RMB 1 billion from 2026 to 2030, the company can fund this capex internally. Historical data shows average operating cash flow of RMB 2.7 billion and average capex of RMB 2.6 billion annually from 2022 to 2025, indicating strong internal cash generation capability. Valuation and Rating: Nomura maintains its 'Buy' rating on Pharmaron. Using a DCF model with a weighted average cost of capital (WACC) of 10.0% and a terminal growth rate of 4.0%, it derives a target price of HKD 27.33. The current share price of HKD 17.92 implies a P/E ratio of 13.2x based on FY26E EPS of RMB 1.22.

Analysis framework

Nomura’s analysis centers on 'strategic alignment' and 'financial feasibility.' First, from a business structure perspective, it identifies the mismatch between Pharmaron’s strength in early-stage CRO and its weakness in commercial CDMO capacity, interpreting this expansion as a critical step toward completing its 'end-to-end' service offering. Second, by analyzing historical operating cash flows versus capex, it confirms the company’s ability to fund new investments internally, mitigating risks of significant equity dilution from external financing. Finally, it employs a DCF valuation model combined with current P/E levels to assess margin of safety and upside potential.

Methodology notes

• Valuation MethodDCF Discounted Cash Flow

  DCF Discounted Cash Flow Model

  This model forecasts a company’s future free cash flows and discounts them using a risk-adjusted weighted average cost of capital (WACC), adding a terminal value to estimate intrinsic value. This report assumes a WACC of 10% and a terminal growth rate of 4% to derive the target price.

• Company Fundamentals & Financial FrameworkFree cash flow analysis

  Internal Resource Capacity to Support Capex

  By comparing historical average operating cash flow against capital expenditure levels, this analysis evaluates whether the company can sustain new project investments without relying on large-scale external financing, demonstrating financial resilience through internal cash generation.

• Industry/Sector Analysis FrameworkUpstream-Midstream-Downstream Industry Chain Transmission

  CRO-to-CDMO Downstream Extension for End-to-End Service Logic

  In the pharmaceutical outsourcing industry, extending from early-stage R&D (CRO) to commercial manufacturing (CDMO) enhances client retention. The report notes that Pharmaron must address its commercial capacity gap to capture the large volume of late-stage clinical projects generated upstream, thereby closing the value chain loop.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Pharmaron (3759.HK)

  Direct beneficiary, resolving commercial CDMO capacity constraints through expansion

  Strengths

  Strong early-stage CRO capabilities; substantial late-stage clinical project pipeline; robust internal cash flow to support capex

  Weaknesses

  Commercial manufacturing currently contributes only 25% of revenue, indicating insufficient capacity

  Risks

  Operational complexity and slower-than-expected ramp-up in utilization of new facilities; competition from other CRO players

Key data

• Total Investment AmountRMB 5 billionFor new CDMO facilities in Hangzhou (RMB 2B) and Shaoxing (RMB 3B)
• Shaoxing Plant Capacity200 tons/yearFor intermediates and APIs targeting obesity, diabetes, and oncology drugs
• Project Completion TimelinePhase I in 2028, Phase II in 2030Construction period of approximately three years
• Commercial Project Revenue Share25%Current share of commercial manufacturing in total revenue, with room for improvement
• Target PriceHKD 27.33Based on DCF model with WACC of 10% and terminal growth rate of 4%
• Current Valuation13.2x FY26E EPSBased on FY26 expected EPS of RMB 1.22

Impact & implications

The report views this capacity expansion as a pivotal strategic move for Pharmaron to transition from an early-stage R&D service provider to a full-spectrum 'end-to-end' solutions partner. By addressing the commercial manufacturing capacity gap, the company is better positioned to retain its pipeline projects through commercialization, enhancing long-term revenue stability. If utilization of the new facilities ramps up as expected, it will significantly strengthen the company’s core competitiveness.

Risks

• Intensifying competition from other CRO/CDMO peers
• Slower-than-expected expansion of overseas subsidiaries
• Management challenges and slower-than-expected utilization ramp-up at new manufacturing facilities

What to watch

• Operational performance of newly built facilities over the coming years
• Speed of capacity utilization ramp-up